Dynamic single-cell systemic immune responses in immunotherapy-treated early-stage HR+ breast cancer patients
Abstract The limited added benefit of immune checkpoint inhibitors in breast cancer indicates the pressing need to identify biomarkers of response to minimize risk and maximize benefit. We used single cell RNA sequencing and T cell receptor (TCR) sequencing of peripheral blood mononuclear cells (for...
Saved in:
| Main Authors: | Xiaopeng Sun, Margaret L. Axelrod, Adrienne G. Waks, Jingxin Fu, Molly DiLullo, Eliezer M. Van Allen, Sara M. Tolaney, Elizabeth A. Mittendorf, Yaomin Xu, Justin M. Balko |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-025-00776-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Molecular analysis of immune checkpoint inhibitor associated erythema nodosum-like toxicity
by: Xiaopeng Sun, et al.
Published: (2025-03-01) -
Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2− Metastatic Breast Cancer
by: Hope S. Rugo, et al.
Published: (2025-03-01) -
Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists
by: Hope S. Rugo, et al.
Published: (2025-08-01) -
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer
by: Sara M Tolaney, et al.
Published: (2025-02-01) -
Recent Advances in Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer
by: Corti C, et al.
Published: (2025-04-01)